logo-loader
HealthPharma & Biotech
Antisense Therapeutics Ltd

Full interview: Antisense Therapeutics further develops therapeutic for Duchenne Muscular Dystrophy with ATL1102

Antisense Therapeutics Limited (ASX:ANP) managing director Mark Diamond updates Proactive on the company’s progress in developing a therapeutic for a severe disease called Duchenne Muscular Dystrophy, or DMD.

The managing director spoke about the importance of the drug ATL1102 that is being progressed through the company’s Phase 2 trial, saying it has shown significant success.

Diamond says some important regulatory interactions necessary for efficient and timely advancement to the next stage of development of ATL1102 are underway.

Quick facts: Antisense Therapeutics Ltd

Price: $0.05

Market: ASX
Market Cap: $21.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Northern Minerals in strategic discussions with government...

Northern Minerals Ltd (ASX:NTU) CEO George Bauk tells Proactive the Australia-based dysprosium mining company will be talking to government agencies in Washington next week to determine how the company can be a supplier to the United States. Currently, China is the world's most dominant...

2 days, 11 hours ago

RNS

Half-year Report

4 days, 20 hours ago

Result of AGM

on 28/6/19

AGM Statement

on 27/6/19

Total Voting Rights

on 21/6/19

2 min read